LEIDEN, NETHERLANDS--(Marketwire - August 05, 2010) -
Leiden, The Netherlands, August 5, 2010. Biotech company Pharming Group NV (“Pharming”) (NYSE Euronext: PHARM) today announced that its current number of outstanding shares has increased from 309,747,614 at July 12, 2010 to 332,865,044 as per today.
The increase of 23,117,430 shares stems from: * 12,536,035 shares in relation to anti-dilution protection shares due to former holders of bonds settled in the fourth quarter of 2009, as announced in the press release on the financial report for the first half of 2010 dated July 21, 2010. The effect of these shares was fully included in the results of the second quarter 2010; * 5,000,000 shares following completion of the DNage spin-off as announced on July 19, 2010; and * 5,581,395 shares issued in relation to the exercise of warrants issued upon entering into EUR7.5 million private bonds in January 2010.
About Pharming Group NV Pharming Group NV is developing innovative products for the treatment of genetic disorders, ageing diseases, specialty products for surgical indications, and nutritional products. On June 24, the European Medicines Agency adopted a positive opinion for Ruconest™ (Rhucin) for the treatment of angioedema attacks. Market Authorization in the European Economic Area is therefore expected to be granted in September 2010. The product is also under development for follow-on indications, i.e. antibody-mediated rejection (AMR) and delayed graft function (DGF) following kidney transplantation. The advanced technologies of the Company include innovative platforms for the production of protein therapeutics, technology and processes for the purification and formulation of these products, as well as technology in the field of DNA repair (via DNage). Recently the partial spin off of DNage was initiated. Additional information is available on the Pharming website,http://www.pharming.com.
This press release contains forward looking statements that involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company to be materially different from the results, performance or achievements expressed or implied by these forward looking statements.
Contact: Ms. Marjolein van Helmond, T: +31 (0)71 52 47 431 or +31 (0)6 109 299 54
[HUG#1436136]
Press release (PDF): http://hugin.info/132866/R/1436136/381299.pdf
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction for further distribution is prohibited.
Source: Pharming Group N.V. via Thomson Reuters ONE
Contact:
Ms. Marjolein van Helmond
T: +31 (0)71 52 47 431 or
+31 (0)6 109 299 54
